Cargando…
Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study
Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic therapy has not been optimized. This study aimed to evaluate the safety and efficacy of cetuximab-containing chemotherapy a...
Autores principales: | Kurosaki, Takashi, Mitani, Seiichiro, Tanaka, Kaoru, Suzuki, Shinichiro, Kanemura, Hiroaki, Haratani, Koji, Fumita, Soichi, Iwasa, Tsutomu, Hayashi, Hidetoshi, Yoshida, Takeshi, Ishikawa, Kazuki, Kitano, Mutsukazu, Otsuki, Naoki, Nishimura, Yasumasa, Doi, Katsumi, Nakagawa, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748051/ https://www.ncbi.nlm.nih.gov/pubmed/32976215 http://dx.doi.org/10.1097/CAD.0000000000001006 |
Ejemplares similares
-
Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
por: Yonesaka, Kimio, et al.
Publicado: (2019) -
Up‐front neck dissection followed by chemoradiotherapy for T1–T3 hypopharyngeal cancer with advanced nodal involvement
por: Sato, Mitsuo P., et al.
Publicado: (2021) -
Gastroparesis as a significant gastrointestinal adverse event during intensive chemotherapy for solid caner: a case report
por: Nakayama, Tomohiro, et al.
Publicado: (2022) -
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
por: Shimizu, Toshio, et al.
Publicado: (2017) -
Treatment of EGFR mutation–positive non–small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report
por: Nonagase, Yoshikane, et al.
Publicado: (2018)